Prediction statistics for AUC and Cmax by mPBPK (n = 52 drugs)
Range
mPBPK (AUC)
mPBPK (Cmax)
Within the range #
Within the range (%)
Within the range #
Within the range (%)
Mild
n = 37
n =25
0.5–2
34
92
24
96
0.5–1.5
30
81
20
80
0.7–1.3
23
62
15
60
> 2
0
0
2
8
< 0.5
3
8
0
0
AFE
1.05
-
1.18
-
Moderate
n = 47
n = 38
0.5–2
44
94
34
89
0.5–1.5
41
87
26
68
0.7–1.3
29
62
20
53
> 2
0
0
5
13
< 0.5
3
6
0
0
AFE
0.95
-
1.21
-
Severe
n = 36
n = 30
0.5–2
32
89
23
77
0.5–1.5
28
78
16
53
0.7–1.3
19
53
11
37
> 2
0
0
8
27
< 0.5
3
8
0
0
AFE
0.90
-
1.42
-
-: no data. #: number of drugs. The number of observations in Table 4 is the total number of observations from mPBPK (Tables 2 and 3) and the additional data analysis of 25 drugs. AFE: average fold error; AUC: area under the curve; Cmax: maximum plasma concentration; mPBPK: minimal physiologically based pharmacokinetic
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation [Internet].[cited 2024 Sep 17]. Available from: https://www.fda.gov/media/116737/download
Drozdzik M, Szelag-Pieniek S, Post M, Zeair S, Wrzesinski M, Kurzawski M, et al. Protein Abundance of Hepatic Drug Transporters in Patients With Different Forms of Liver Damage.Clin Pharmacol Ther. 2020;107:1138–48. [DOI] [PubMed]
McConn DJ 2nd, Lin YS, Mathisen TL, Blough DK, Xu Y, Hashizume T, et al. Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis.Clin Pharmacol Ther. 2009;85:387–93. [DOI] [PubMed] [PMC]
Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.Clin Pharmacokinet. 2010;49:189–206. [DOI] [PubMed]
Edginton AN, Willmann S. Physiology-based simulations of a pathological condition.Clin Pharmacokinet. 2008;47:743–52. [DOI] [PubMed]
Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, et al. Physiologically-Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective.Clin Pharmacol Ther. 2021;110:297–310. [DOI] [PubMed] [PMC]
Mahmood I, Tegenge MA. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.J Clin Pharmacol. 2019;59:189–97. [DOI] [PubMed]
Björkman S. Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs.Br J Clin Pharmacol. 2005;59:691–704. [DOI] [PubMed] [PMC]
Björkman S. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.J Pharmacokinet Pharmacodyn. 2003;30:285–307. [DOI] [PubMed]
Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models.J Pharmacokinet Pharmacodyn. 2012;39:711–23. [DOI] [PubMed] [PMC]
Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.J Pharmacokinet Pharmacodyn. 2013;40:597–607. [DOI] [PubMed] [PMC]
Zhao J, Cao Y, Jusko WJ. Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model.Pharm Res. 2015;32:3269–81. [DOI] [PubMed] [PMC]
Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.MAbs. 2018;10:1144–56. [DOI] [PubMed] [PMC]
Mahmood I, Tegenge MA. Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients.J Clin Pharmacol. 2021;61:S108–16. [DOI] [PubMed]
Mahmood I. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.Drugs R D. 2020;20:377–87. [DOI] [PubMed] [PMC]
Mahmood I, Ahmad T, Mansoor N, Sharib SM. Prediction of Clearance in Neonates and Infants (≤ 3 Months of Age) for Drugs That Are Glucuronidated: A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling.J Clin Pharmacol. 2017;57:476–83. [DOI] [PubMed]
Mahmood I. A comparison of different methods for the first-in-pediatric dose selection.J Clin Transl Res. 2022;8:369–81. [PubMed] [PMC]
Li R, Barton HA, Maurer TS. A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions.CPT Pharmacometrics Syst Pharmacol. 2015;4:338–49. [DOI] [PubMed] [PMC]
